All Oncology News

Regional Cancer Care Associates LLC, one of the nation’s largest networks of oncology specialists, has appointed Iuliana Shapira, MD, its chief medical officer.

Sandoz has entered into an agreement with EirGenix, Inc., to commercialize the proposed trastuzumab biosimilar EG12014 for use as a treatment of patients with HER2-positive breast and select gastric cancers.

Nathan T. Connell, MD, MPH, shares key updates in the rapidly evolving treatment paradigms of benign hematologic disorders.

A supplemental new drug application has been submitted to the FDA for the approval of apalutamide (Erleada) for use as a treatment of patients with metastatic castration-sensitive prostate cancer.

The European Medicines Agency's Committee for Medicinal Products for Human Use has backed approval of talazoparib (Talzenna) for adult patients with HER2-negative locally advanced or metastatic breast cancer harboring germline BRCA1/2 mutations.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended that the conditional marketing authorization for olaratumab be revoked following results of the ANNOUNCE study, which did not demonstrate a survival benefit with the PDGFRα antagonist in combination with doxorubicin versus doxorubicin alone in patients with advanced or metastatic soft tissue sarcoma.

OncLive has announced its steering committee for the first OncLive® Global Expo, which will take place Oct. 11-13, 2019, at the Orlando World Center Marriott in Orlando, Florida.

The European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of cemiplimab for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation, according to Regeneron Pharmaceuticals, the manufacturer of the PD-1 inhibitor.

USC Norris Comprehensive Cancer Center has launched a study to determine how financial assistance for costs associated with clinical trial participation might increase enrollment, particularly among low-income patients and racial and ethnic minorities.

The FDA has granted a priority review designation to a new drug application for darolutamide for use as a treatment for patients with nonmetastatic castration-resistant prostate cancer.

The European Committee for Medicinal Products for Human Use has recommended approval of olaparib as a frontline maintenance treatment for patients with BRCA-mutant advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response following first-line platinum-based chemotherapy.

Christine N. Duncan, MD, discusses the current components of CAR T-cell therapy in pediatric acute lymphoblastic leukemia.

Ronan J. Kelly, MD, MBA, addresses the paradigm shift in stage III unresectable non–small cell lung cancer before delving into the complex field of ALK-rearranged disease.

A marketing authorization application has been submitted to the European Medicines Agency for luspatercept for the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndrome–associated anemia with ring sideroblasts who require red blood cell transfusions and have not received or are ineligible to receive erythropoiesis-stimulating agents.

The combination of pembrolizumab (Keytruda) and chemotherapy did not improve overall survival or progression-free survival compared with standard chemotherapy alone for the frontline treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Eli Lilly and Company has announced that it is withdrawing its PDGFRα antagonist olaratumab from the market for the treatment of patients with advanced soft tissue sarcoma.

The combination of lenalidomide (Revlimid) with rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; R2-CHOP) did not improve progression-free survival compared with placebo and R-CHOP as a frontline therapy in patients with activated B-cell-type diffuse large B-cell lymphoma, missing the primary endpoint of the phase III ROBUST trial.

OncLive® is proud to announce the inductees of the 2019 Giants of Cancer Care® recognition program.

Aditya Bardia, MD, MPH, discusses the potential role of circulating tumor cells and circulating tumor DNA testing in patients with breast cancer.

Eric S. Nadler, MD, discusses key data with immunotherapy in the treatment of patients with metastatic squamous non–small cell lung cancer.

Tagraxofusp led to a 90% overall response rate as a first-line therapy in patients with blastic plasmacytoid dendritic cell neoplasm.

Kartik Konduri, MD, discusses the use of combination therapies and newer agents in patients with targetable driver mutations.

Clinical outcomes were found to be consistent among transplant-eligible patients with mantle cell lymphoma, irrespective of the chemoimmunotherapy induction regimen that was administered.

David P. Mason, MD, discusses the available treatment approaches for patients with locally advanced non–small cell lung cancer.

Kristen Ciombor, MD, MSCI, discusses the promise of liquid biopsies in the rapidly evolving metastatic colorectal cancer paradigm and the potential implications of the COLOMATE trial.

Rutgers Cancer Institute of New Jersey, the state’s only Comprehensive Cancer Center as recognized by the National Cancer Institute, has been awarded a $15.1 million grant as part of its successful 2019 redesignation.

A new VENTANA HER2 dual in situ hybridization companion diagnostic assay has launched to identify HER2 amplification for patients with breast cancer and gastric cancer who could be eligible to receive trastuzumab.

Wistar’s Cancer Center became the first National Cancer Institute-designated basic cancer center in the nation in 1972 and has held this national recognition for the past 46 years.

Geoffrey Y. Ku, MD, discusses data of durvalumab plus tremelimumab in a biomarker-selected patient population and sheds light on the role of immunotherapy in patients with advanced gastric cancer.

Omar Nadeem, MD, highlights exciting approaches that have emerged in relapsed/refractory myeloma, such as CAR T-cell therapy, and shares unanswered questions that future research should address.